FDA & Government News

FDA Approves First Therapy for Allergic Fungal Rhinosinusitis

Patients with allergic fungal rhinosinusitis now have a targeted biologic option.

Share

Dupilumab (Dupixent) has been approved by the FDA for treating allergic fungal rhinosinusitis (AFRS) in patients aged 6 years and older. This marks the first FDA-approved therapy specifically for AFRS, a rare subtype of chronic rhinosinusitis caused by an allergic response to fungi, which can lead to serious complications such as bone erosion and visual impairment. Clinical trials showed that dupilumab significantly improved sinus opacification and reduced the need for corticosteroids and surgery over a 52-week period without identifying new safety signals.

Original Source(s)

FDA Approves First Therapy for Allergic Fungal Rhinosinusitis

Patients with allergic fungal rhinosinusitis now have a targeted biologic option.

  • by Kathryn Wighton

  • February 25, 2026

  • 2 min

Related Content

Connecting the Diagnostic Dots in HIES

Clinical case report highlights how classic features of STAT3 hyper-IgE syndrome can be routinely missed in pediatric practice

Staffing, Flexibility Top Nurses' List to Return

Two-thirds of former hospital nurses would consider coming back if workplace conditions improved, survey finds

Vaccine Playbook Rewrite: Who’s In Charge?

HHS Secretary Robert F. Kennedy Jr.’s changes at the CDC are prompting states and medical societies to issue independent vaccine recommendations, challenging long-standing national immunization policy.